TORRENT PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 324.1%

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Markets will remain closed on 12th November, 2019 on account of Guru Nanak Jayanti.

TORRENT PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 324.1%
Thu, 31 Jan

TORRENT PHARMA has announced its results for the quarter ended December 2018. Here is a detailed performance review of the same:

TORRENT PHARMA Quarterly Financials

No. of Mths
Qtr. Ending
3
Dec-17*
3
Sep-18*
3
Dec-18*
QoQ ChangeYoY Change
Net SalesRs m14,77018,94020,5108.3%38.9%
Other incomeRs m74010030-70.0%-95.9%
TurnoverRs m15,51019,04020,5407.9%32.4%
ExpensesRs m11,18014,21014,9004.9%33.3%
Gross profitRs m3,5904,7305,61018.6%56.3%
DepreciationRs m9401,5201,5602.6%66.0%
InterestRs m8001,2601,3305.6%66.3%
Profit before taxRs m2,5902,0502,75034.1%6.2%
TaxRs m2,01026029011.5%-85.6%
Profit after taxRs m5801,7902,46037.4%324.1%
Gross profit margin%24.325.027.4
Effective tax rate%77.612.710.5
Net profit margin%3.79.412.0
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster


Year-on-Year Performance:
  • The company's operating income during the quarter grew 38.9% on a year-on-year (YoY) basis. The expenses were up by 33.3% YoY during the same period.
  • The company's operating profit increased by 56.3% YoY during the quarter. Consequently, operating profit margins witnessed a growth and stood at 27.4% in 3QFY19 as against 24.3% in 3QFY18.
  • Depreciation charges increased by 66.0% and finance costs increased by 66.3% YoY, respectively.
  • Other income declined by 95.9% YoY during the quarter.
  • Net profit for the quarter increased by 324.1% YoY. Net profit margins during the quarter increased from 3.7% in 3QFY18 to 12.0% in 3QFY19.
Quarter-on-Quarter Performance:
  • The company's operating income during the quarter grew 8.3% on a quarter-on-quarter (QoQ) basis. The expenses were up by 4.9% QoQ during the same period.
  • The company's operating profit increased by 18.6% QoQ during the quarter. Consequently, operating profit margins witnessed a growth and stood at 27.4% in 3QFY19 as against 25.0% in 2QFY18.
  • Net profit for the quarter increased by 37.4% QoQ, while net profit margins increased from 9.4% in 2QFY18 to 12.0% in 3QFY19.

To see how TORRENT PHARMA has performed over the last eight quarters, please visit here.

TORRENT PHARMA Share Price Performance

Over the last one year, TORRENT PHARMA share price has moved up from Rs 1,363.0 to Rs 1,821.0, registering a Gain of Rs 458.1 or around 33.6%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 13,845.6 (up 0.6%). Over the last one year it has moved down from 14,559.4 to 13,845.6, a gain of 714 points (down 4.9%).

Overall, the S&P BSE SENSEX is up 0.3% over the year.

Current Valuations

At the current price of Rs 1,821.0, the price to earnings (P/E) ratio of TORRENT PHARMA stands at 37.8 times its trailing twelve months earnings, while its price to book value (P/BV) ratio stands at 6.7 times.

Equitymaster requests your view! Post a comment on "TORRENT PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 324.1%". Click here!

  

Related Views on News

TORRENT PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 36.3% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 36.3% YoY). Sales on the other hand came in at Rs 20 bn (up 5.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Ditch the Risky Fixed Deposits for Safer 'Bluechip Deposits'(Profit Hunter)

Oct 30, 2019

Most people think stocks are riskier than fixed deposits and bonds. The last quarter century proves otherwise.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Nov 11, 2019 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 8-QTR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS